Michel Janicott

Michel Janicott

Company: inteRNA Technologies

Job title: Chief Development Officer


Translational Medicine with INT-1B3 (LNP-Formulated miRNA-193a-3p Mimic): From Bench to Bedside 9:00 am

MicroRNAs as innovative approach for therapeutic intervention in oncology Pre-clinical development of microRNA mimic in oncology Lessons learnt on translation from pre-clinical to clinical PKPD/toxicologyRead more

day: Day Two

Improving Toxicology & Pharmacology of Emerging Non-Coding RNA Therapeutics towards the Clinic 9:00 am - 12:00 pm

Taking into account the pre-clinical advancements of non-coding RNA therapeutics, there is now a greater necessity to characterize ways to improve their toxicology and pharmacology profile to better understand their mechanisms of action whilst maintaining efficacy. Combating the challenges associated with the toxicology and pharmacology of non-coding RNA therapeutics requires a deeper focus and will…Read more

day: Workshop A

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.